Researchers from the Chinese Academy of Medical Sciences and Beijing Hospital have launched a groundbreaking early‑stage clinical trial that pairs donor natural‑killer (NK) cells with the standard chemotherapy drugs gemcitabine and S‑1 for patients with advanced pancreatic cancer. Published on December 9, 2025 in *Signal Transduction and Targeted Therapy*, the phase 1b/2 study (ChiCTR1900021764) showed that the combined treatment is safe and hints at early signs of effectiveness, prompting calls for larger trials. Pancreatic cancer remains one of the deadliest cancers, with fewer than 10 % of patients surviving five years, so fresh therapeutic approaches are urgently needed. Unlike T‑cell therapies, NK cells can attack tumor cells without prior sensitization and can be produced “off‑the‑shelf,” making them attractive for rapid clinical use. Multi‑omics analysis of patients’ blood revealed specific NK and T‑cell subsets that may predict how well patients respond, offering new insight into the immune dynamics at play. While earlier NK‑cell work has shown promise in blood cancers and liver cancer, this is among the first trials to test NK cells alongside gemcitabine + S‑1 in pancreatic cancer. The early results are encouraging and set the stage for more extensive research into NK‑cell‑based combos as a potential lifeline for a disease that has long lacked effective treatments.
Read more